Hana Pharm. Co., Ltd.
About Hana Pharm. Co., Ltd.
Categories
-
Country/Region:Korea, Republic Of
-
On CPHI since:2025
-
Employees:500 - 999
Company types
Meet us at
CPHI South East Asia 2026
QSNCC, Bangkok, Thailand
08 Jul 2026 - 10 Jul 2026
CPHI Milan 2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
Products from Hana Pharm. Co., Ltd. (6)
-
Product Dexmedetomidine HCI
-Active Ingredients: Dexmedetomidine HCI -Dosage: 200mcg/2mL -Indication Sedation under intensive care management Conscious sedation for non-intubated patients during surgery and procedures -GMP: Korea GMP -Stability: Zone IV b -
Product Isoflurane
-Active Ingredients: Isoflurane -Dosage: 100mL -Indication General anesthesia -GMP: Korea GMP -Stability: Zone IV b -
Product Propofol
-Active Ingredients: Propofol -Dosage: 120mg/12mL, 200mg/20mL -Indication Induction and maintenance of general anesthesia Sedation of ventilated patients receiving intensive care Sedation of surgical and diagnostic procedures -GMP: Korea GMP -Stability: Zone IV b -
Product Remimazolam
-Active Ingredients: Remimzaolam Bsylate -Excipients: Dextran 40, Lactose monohydrate, sodium hydroxide, hydrochloric acid -Dosage: 20mg, 50mg -Indication: 1. Byfavo Inj. 20mg The induction and maintenance of general anesthesia The induction and maintenance of procedural sedation in adults undergoing proce... -
Product Sevoflurane
-Active Ingredients: Sevoflurane -Dosage: 250mL -Indication General anesthesia -GMP: Korea GMP -Stability: Zone IV b -
Product Byfavo Inj.
Byfavo Inj (remimazolam 20mg, 50mg) is an ultra–short–acting IV benzodiazepine sedative/anesthetic. It offers very rapid onset and offset of sedation, allowing quick patient recovery. In the body, remimazolam is rapidly metabolized by tissue esterases (not by CYP), which contributes to its brief duration a...
